Arena Pharmaceuticals, Eisai Expand Marketing and Supply Agreement for BELVIQ

Arena Pharmaceuticals (NASDAQ: ARNA ) and Eisai announced today the expansion of the BELVIQ® (lorcaserin HCl) marketing and supply agreement between Arena Pharmaceuticals, Inc.'s wholly owned subsidiary, Arena Pharmaceuticals GmbH, and Eisai Inc. along with its parent company Eisai Co., Ltd. The expanded agreement provides Eisai with exclusive commercialization